IL2 and neoplasm: Follow‐up studies have continued to devise more sophisticated approaches to manipulate IL‐2 binding to its alpha and beta receptors, generating new IL‐2 variants capable of engaging either the immune‐effector or immune‐suppressive arm of the IL‐2 response to improve anti‐tumour responses or promote tolerance respectively (reviewed in [33, 34, 35]).